US EditionIntas Pharmaceuticals and Accord BioPharma Expand Global Pegfilgrastim Footprint with UDENYCA Acquisition - Express Pharma
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Intas Pharmaceuticals acquires Udenyca from Coherus BioSciences
This acquisition expands Intas and Accord’s biosimilar portfolio approved by the FDA and expedites their growth in the global market. With the acquisition, Intas’ US speciality business Accord The post Intas Pharmaceuticals acquires Udenyca from Coherus BioSciences appeared first on Pharmaceutical Business review.
Accord Healthcare [Newsroom]Ahmedabad, India (ots/PRNewswire) - Intas Pharmaceuticals, in cooperation with its global subsidiaries operating under the Accord brand, has its position as one of the world's leading providers of Pegfilgrastim after the ... Continue reading here...Original content of: Accord Healthcare, news transmitted by currently
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium